McClellan’s FDA Legacy? Decisive Role In Product Development Priorities
This article was originally published in The Gray Sheet
Executive Summary
FDA's "critical path" initiative to help streamline R&D costs and product development schedules is positioning the agency to eventually seek grant-making authority from Congress
You may also be interested in...
CDRH “Innovation Initiative” Highlights Efforts To Speed Premarket Process
FDA seeks to underscore its commitment to help innovative new medical devices get to market more quickly with a report unveiled May 22
CDRH “Innovation Initiative” Highlights Efforts To Speed Premarket Process
FDA seeks to underscore its commitment to help innovative new medical devices get to market more quickly with a report unveiled May 22
CBER’s Goodman Eyes Tissue, Blood Test Innovation Through Post-9/11 Lens
Development of tests to screen blood and tissues for multiple pathogens would help safeguard public health and national security, Center for Biologics Evaluation & Research Director Jesse Goodman, MD/MPH, stresses in an Aug. 19 New England Journal of Medicine editorial
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: